Views: 0 Author: Site Editor Publish Time: 2025-12-25 Origin: Site
Biotechnology, a high-investment, long-cycle, and high-barrier track upstream of various industrial chains, is anchoring the promising new blue ocean of pet health with unprecedented determination and posture. In 2025, Novonesis, a global leader in the biotechnology field, officially announced the establishment of a Pet Business Unit under its Earth Health segment, marking its formal entry into the Chinese pet market. According to official sources, the business unit focuses on functional core raw materials for pets, with key emphasis on enzyme preparations and probiotic products, aiming to bring innovative biotech-based solutions to the global pet industry.
A key question arises: when a global leading enterprise with a century of research experience turns its attention to the pet health track, what disruptive variables will it inject into the industry? And how will it redefine the future standards of pet nutrition and health?
Novonesis was formed by the merger of two long-established companies: Novozymes and Chr. Hansen.
In December 2022, Novozymes, a global leader in industrial enzymes and microbial preparations, and Chr. Hansen, a top global probiotic company, reached a merger agreement. In January 2024, the proposed merger of the two companies was officially completed, announcing the formal establishment of Novonesis.
The name "Novonesis" is derived from the Greek word "genesis," meaning "origin" or "beginning." It signifies the arrival of a new era of biological solutions, where biotech innovation will provide answers to a series of major challenges facing humanity. Its official Chinese name "诺和新元" (Nuòhé Xīnyuán) also embodies the same expectations, upholding the same philosophy while endowing it with connotations of traditional Chinese culture.
Currently, Novonesis has two core business segments: the "Food & Health Biosolutions Segment," which focuses on biotech solutions for human health, food, and beverages; and the "Earth Health Biosolutions Segment," which is committed to biotech solutions for animal and plant health, home care, and various industrial applications.
In 2025, Novonesis officially established the Pet Business Unit under the Earth Health segment, marking its formal entry into the Chinese pet market. Interestingly, Novozymes and Chr. Hansen—the two components of Novonesis—have previously developed pet-related products for the Chinese market as global leaders in enzymes and probiotics, providing strong support for the new business unit's expansion.
As a global leading biological solutions enterprise, Novonesis has established extensive industry recognition and brand reputation in the Chinese pet market with its profound accumulation in enzymes and probiotics. Since its establishment, the Pet Business Unit has relied on the group's technological and supply chain advantages to reach in-depth cooperation intentions with many well-known domestic pet brands and large production factories in just one year, continuously promoting the innovative application of biotechnology in pet nutrition and health.
"In the next step, localized innovative R&D and production will also be a key focus of Novonesis' business development in the Chinese pet market," according to official sources. Novonesis currently has more than 40 R&D and application centers and over 20 production bases worldwide, building a global network consisting of R&D, application centers, and manufacturing bases. This enables it to transform cutting-edge R&D achievements into commercial products and promote them rapidly.
Specifically in China, Novonesis has more than 1,000 employees. Its corporate headquarters and R&D center are located in Beijing, with a multi-purpose enzyme production pilot facility in Tianjin, a dedicated enzyme production base in Suzhou, a microbial production base in Shenyang, and sales and technical centers in Shanghai and Guangzhou. Relying on these three production bases, Novonesis has now realized the plan for most local production in China. At the same time, Novonesis is actively preparing for more capacity expansion and is expected to develop more production lines in the Chinese market.
